Pfizer Share Price
Sector: Major Drugs
5694.00 +20.65 (0.36%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5639.70
Today’s High
5787.60
52 Week Low
3742.90
52 Week High
6452.85
5671.00 -6.50 (-0.11%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5636
Today’s High
5755
52 Week Low
3701
52 Week High
6451.15
Key Metrics
- Market Cap (In Cr) 26280.83
- Beta 0.5
- Div. Yield (%) 0.62
- P/B 6.16
- TTM P/E 23.87
- Peg Ratio 4.33
- Sector P/E 22.67
- D/E 0
- Open Price 5747
- Prev Close 5673.35
Pfizer Analysis
Price Analysis
-
1 Week0.24%
-
3 Months42.9%
-
6 Month16.46%
-
YTD7.5%
-
1 Year23.17%
Risk Meter
- 30% Low risk
- 30% Moderate risk
- 30% Balanced Risk
- 30% High risk
- 30% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 1
- 1
- 1
- 0.00
- Hold
- 0.00
- 0.00
- 0.00
- 1
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 3
- 3
- 3
- 3
Pfizer News
FDA expands warning about rare heart side effect in two leading Covid vaccines
1 min read . 26 Jun 2025Despite trade war, US drug companies turn to China for key cancer treatments
4 min read . 06 Jun 2025Pfizer share price rises 13% post Q4 Results, dividend announcement: Do you own?
1 min read . 20 May 2025Pfizer Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 2281.35
- Selling/ General/ Admin Expenses Total
- 371.33
- Depreciation/ Amortization
- 60.79
- Other Operating Expenses Total
- 359.34
- Total Operating Expense
- 1601.91
- Operating Income
- 679.44
- Net Income Before Taxes
- 1016.09
- Net Income
- 767.6
- Diluted Normalized EPS
- 139.25
- Period
- 2025
- Total Assets
- 4911.11
- Total Liabilities
- 693.7
- Total Equity
- 4217.41
- Tangible Book Valueper Share Common Eq
- 801.27
- Period
- 2025
- Cashfrom Operating Activities
- 659.75
- Cashfrom Investing Activities
- -71.34
- Cashfrom Financing Activities
- -205.34
- Net Changein Cash
- 383.07
- Period
- 2024
- Total Revenue
- 2193.17
- Selling/ General/ Admin Expenses Total
- 688.51
- Depreciation/ Amortization
- 62.28
- Other Operating Expenses Total
- 16.96
- Total Operating Expense
- 1601.81
- Operating Income
- 591.36
- Net Income Before Taxes
- 746.07
- Net Income
- 551.33
- Diluted Normalized EPS
- 119.72
- Period
- 2024
- Total Assets
- 4228.78
- Total Liabilities
- 633.24
- Total Equity
- 3595.54
- Tangible Book Valueper Share Common Eq
- 663.15
- Period
- 2024
- Cashfrom Operating Activities
- 256.84
- Cashfrom Investing Activities
- 53.7
- Cashfrom Financing Activities
- -235.14
- Net Changein Cash
- 75.4
- Period
- 2023
- Total Revenue
- 2424.76
- Selling/ General/ Admin Expenses Total
- 650.55
- Depreciation/ Amortization
- 104.02
- Other Operating Expenses Total
- 30.07
- Total Operating Expense
- 1680.32
- Operating Income
- 744.44
- Net Income Before Taxes
- 824.01
- Net Income
- 623.93
- Diluted Normalized EPS
- 130.83
- Period
- 2023
- Total Assets
- 4000.73
- Total Liabilities
- 793.43
- Total Equity
- 3207.3
- Tangible Book Valueper Share Common Eq
- 576.11
- Period
- 2023
- Cashfrom Operating Activities
- 355.68
- Cashfrom Investing Activities
- -36.05
- Cashfrom Financing Activities
- -345.79
- Net Changein Cash
- -26.16
- Period
- 2022
- Total Revenue
- 2610.99
- Selling/ General/ Admin Expenses Total
- 740.31
- Depreciation/ Amortization
- 113.61
- Other Operating Expenses Total
- 18.38
- Total Operating Expense
- 1879.37
- Operating Income
- 731.62
- Net Income Before Taxes
- 772.89
- Net Income
- 612.56
- Diluted Normalized EPS
- 133.1
- Period
- 2022
- Total Assets
- 3900.51
- Total Liabilities
- 1036.1
- Total Equity
- 2864.41
- Tangible Book Valueper Share Common Eq
- 490.16
- Period
- 2022
- Cashfrom Operating Activities
- 667.08
- Cashfrom Investing Activities
- -575.02
- Cashfrom Financing Activities
- -180.51
- Net Changein Cash
- -88.45
- Period
- 2021
- Total Revenue
- 2238.55
- Selling/ General/ Admin Expenses Total
- 633.05
- Depreciation/ Amortization
- 108.02
- Other Operating Expenses Total
- 28.26
- Total Operating Expense
- 1625.23
- Operating Income
- 613.32
- Net Income Before Taxes
- 668.72
- Net Income
- 497.61
- Diluted Normalized EPS
- 108.07
- Period
- 2021
- Total Assets
- 3265.9
- Total Liabilities
- 872.86
- Total Equity
- 2393.04
- Tangible Book Valueper Share Common Eq
- 376.12
- Period
- 2021
- Cashfrom Operating Activities
- 427.33
- Cashfrom Investing Activities
- -468.84
- Cashfrom Financing Activities
- -1571.07
- Net Changein Cash
- -1612.58
- Period
- 2020
- Total Revenue
- 2151.65
- Selling/ General/ Admin Expenses Total
- 692.65
- Depreciation/ Amortization
- 101.86
- Other Operating Expenses Total
- 22.81
- Total Operating Expense
- 1639.57
- Operating Income
- 512.08
- Net Income Before Taxes
- 642.49
- Net Income
- 509.13
- Diluted Normalized EPS
- 106.14
- Period
- 2020
- Total Assets
- 4405.4
- Total Liabilities
- 1009.91
- Total Equity
- 3395.49
- Tangible Book Valueper Share Common Eq
- 583.22
- Period
- 2020
- Cashfrom Operating Activities
- 323.18
- Cashfrom Investing Activities
- 1530.32
- Cashfrom Financing Activities
- -163.52
- Net Changein Cash
- 1689.98
- Period
- 2019
- Total Revenue
- 2081.5
- Selling/ General/ Admin Expenses Total
- 665.24
- Depreciation/ Amortization
- 70
- Other Operating Expenses Total
- 22.59
- Total Operating Expense
- 1546.84
- Operating Income
- 534.66
- Net Income Before Taxes
- 659.91
- Net Income
- 429.05
- Diluted Normalized EPS
- 89.67
- Period
- 2019
- Total Assets
- 3939.99
- Total Liabilities
- 928.65
- Total Equity
- 3011.34
- Tangible Book Valueper Share Common Eq
- 487.19
- Period
- 2019
- Cashfrom Operating Activities
- 97.81
- Cashfrom Investing Activities
- 35.12
- Cashfrom Financing Activities
- -109.85
- Net Changein Cash
- 23.08
- Period
- 2025-03-31
- Total Revenue
- 591.91
- Selling/ General/ Admin Expenses Total
- 82.91
- Depreciation/ Amortization
- 16.4
- Other Operating Expenses Total
- 79.02
- Total Operating Expense
- 380.81
- Operating Income
- 211.1
- Net Income Before Taxes
- 425.8
- Net Income
- 330.94
- Diluted Normalized EPS
- 42.98
- Period
- 2025-03-31
- Total Assets
- 4911.11
- Total Liabilities
- 693.7
- Total Equity
- 4217.41
- Tangible Book Valueper Share Common Eq
- 801.27
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 659.75
- Cashfrom Investing Activities
- -71.34
- Cashfrom Financing Activities
- -205.34
- Net Changein Cash
- 383.07
- Period
- 2024-12-31
- Total Revenue
- 537.99
- Selling/ General/ Admin Expenses Total
- 96.29
- Depreciation/ Amortization
- 14.8
- Other Operating Expenses Total
- 99.15
- Total Operating Expense
- 406.8
- Operating Income
- 131.19
- Net Income Before Taxes
- 172.44
- Net Income
- 127.6
- Diluted Normalized EPS
- 27.89
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 588.59
- Selling/ General/ Admin Expenses Total
- 100.76
- Depreciation/ Amortization
- 14.99
- Other Operating Expenses Total
- 87.86
- Total Operating Expense
- 414.33
- Operating Income
- 174.26
- Net Income Before Taxes
- 215.23
- Net Income
- 158.35
- Diluted Normalized EPS
- 34.61
- Period
- 2024-09-30
- Total Assets
- 4458.6
- Total Liabilities
- 707.73
- Total Equity
- 3750.87
- Tangible Book Valueper Share Common Eq
- 698.2
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 349.43
- Cashfrom Investing Activities
- -244.21
- Cashfrom Financing Activities
- -181.88
- Net Changein Cash
- -76.66
- Period
- 2024-06-30
- Total Revenue
- 562.86
- Selling/ General/ Admin Expenses Total
- 91.37
- Depreciation/ Amortization
- 14.6
- Other Operating Expenses Total
- 93.31
- Total Operating Expense
- 399.97
- Operating Income
- 162.89
- Net Income Before Taxes
- 202.62
- Net Income
- 150.71
- Diluted Normalized EPS
- 32.94
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 546.63
- Selling/ General/ Admin Expenses Total
- 75.11
- Depreciation/ Amortization
- 13.75
- Other Operating Expenses Total
- 92.75
- Total Operating Expense
- 370.95
- Operating Income
- 175.68
- Net Income Before Taxes
- 243.86
- Net Income
- 178.86
- Diluted Normalized EPS
- 39.09
- Period
- 2024-03-31
- Total Assets
- 4228.78
- Total Liabilities
- 633.24
- Total Equity
- 3595.54
- Tangible Book Valueper Share Common Eq
- 663.15
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 256.84
- Cashfrom Investing Activities
- 53.7
- Cashfrom Financing Activities
- -235.14
- Net Changein Cash
- 75.4
- Period
- 2023-12-31
- Total Revenue
- 539.97
- Selling/ General/ Admin Expenses Total
- 89.37
- Depreciation/ Amortization
- 17.55
- Other Operating Expenses Total
- 115.49
- Total Operating Expense
- 397.02
- Operating Income
- 142.95
- Net Income Before Taxes
- 175.94
- Net Income
- 129.98
- Diluted Normalized EPS
- 27.14
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Pfizer Technical
Moving Average
SMA
- 5 Day5648.22
- 10 Day5752.11
- 20 Day5708.58
- 50 Day4950.45
- 100 Day4553.91
- 300 Day4970.88
Pfizer Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aurobindo Pharma
- 1119.5
- -3.65
- -0.32
- 1592.55
- 994.35
- 65020.74
- Pfizer
- 5694
- 20.65
- 0.36
- 6452.85
- 3742.9
- 26280.83
- Astrazeneca Pharma India
- 8889.65
- 151.3
- 1.73
- 10653.05
- 6160.25
- 22224.13
- Neuland Laboratories
- 12122
- 160.95
- 1.35
- 18089.55
- 6552
- 15537.01
- Unichem Laboratories
- 593
- -4.55
- -0.76
- 949.85
- 510.8
- 4177.5
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aurobindo Pharma
- 18.73
- 1.99
- 12.95
- 12.38
- Pfizer
- 40.02
- 6.04
- 19.24
- 25.99
- Astrazeneca Pharma India
- 118.02
- 28.71
- 18.74
- 9.43
- Neuland Laboratories
- 76.08
- 10.11
- 17.29
- 14.2
- Unichem Laboratories
- 30.83
- 1.72
- -0.54
- -0.88
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 19-May-25
- Audited Results & Special Dividend
- 31-Jan-25
- Quarterly Results
- 28-Oct-24
- Quarterly Results
- 29-Jul-24
- Quarterly Results
- 17-May-24
- Audited Results & Final Dividend
- 09-Feb-24
- Quarterly Results
- 28-Oct-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 15-May-23
- Audited Results & Final Dividend
- 09-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 21-Jul-25
- 19-May-25
- AGM
- 28-Aug-24
- 09-Aug-24
- AGM
- 02-Apr-24
- 29-Feb-24
- POM
- 09-Jan-24
- 07-Dec-23
- POM
- 18-Aug-23
- 15-May-23
- AGM
- 26-Aug-22
- 20-May-22
- AGM
- 19-Aug-21
- 28-Jul-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 19-May-25
- 09-Jul-25
- 09-Jul-25
- 35
- 20-May-25
- 09-Jul-25
- 09-Jul-25
- 130
- 17-May-24
- 21-Aug-24
- 21-Aug-24
- 35
- 15-May-23
- 11-Aug-23
- 11-Aug-23
- 35
- 16-May-23
- 11-Aug-23
- 11-Aug-23
- 5
- 06-Sept-22
- 20-Sept-22
- 19-Sept-22
- 30
- 27-May-21
- -
- 11-Aug-21
- 5
- 26-May-21
- -
- 11-Aug-21
- 30


